Last updated on January 2020

A Phase Ib Study to Evaluate the Safety Tolerability and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)


Brief description of study

The study consists of 2 parts: Dose Escalation phase (Part A) and Expansion phase (Part B). The dose escalation phase will evaluate the safety, tolerability, and PK of avelumab in combination with M9241 in subjects with locally advanced, unresectable, or metastatic solid tumors. Expansion phase will assess the safety and clinical activity of the combination regimen in selected tumor types. In Expansion phase subjects who have completed the combination treatment of avelumab at a given dose level of M9241, a safety review will be performed by the Safety monitoring committee in order to make a decision on the next dose level. Successive cohorts of 3 to 6 subjects will be treated with escalating doses of M9241 with avelumab intravenous (IV).

Clinical Study Identifier: NCT02994953

Find a site near you

Start Over

Amsterdam UMC, Locatie VUMC

Amsterdam, Netherlands
0.24miles
  Connect »

Antoni van Leeuwenhoek Ziekenhuis

Amsterdam, Netherlands
0.24miles
  Connect »